Research / Development Innovation Lab, Journal ArticleFeb 10, 2022

Testing fractional doses of COVID-19 vaccines

Witold Więcek, Amrita Ahuja, Esha Chaudhuri, Michael Kremer, Alexandre Simoes Gomes, Christopher M. Snyder, Alex Tabarrok, Brandon Joel Tan

Due to the enormous economic, health, and social costs of the COVID-19 pandemic, there are high expected social returns to investing in parallel in multiple approaches to accelerating vaccination. We argue there are high expected social returns to investigating the scope for lowering the dosage of some COVID-19 vaccines. While existing evidence is not dispositive, available clinical data on the immunogenicity of lower doses combined with evidence of a high correlation between neutralizing antibody response and vaccine efficacy suggests that half or even quarter doses of some vaccines could generate high levels of protection, particularly against severe disease and death, while potentially expanding supply by 450 million to 1.55 billion doses per month, based on supply projections for 2021. An epidemiological model suggests that, even if fractional doses are less effective than standard doses, vaccinating more people faster could substantially reduce total infections and deaths. The costs of further testing alternative doses are much lower than the expected public health and economic benefits. However, commercial incentives to generate evidence on fractional dosing are weak, suggesting that testing may not occur without public investment. Governments could support either experimental or observational evaluations of fractional dosing, for either primary or booster shots. Discussions with researchers and government officials in multiple countries where vaccines are scarce suggests strong interest in these approaches.

More Research From These Scholars

BFI Working Paper Oct 15, 2021

Water Treatment and Child Mortality: Evidence from Kenya

Johannes Haushofer, Michael Kremer, Ricardo Maertens, Brandon Joel Tan
Topics:  Economic Mobility & Poverty
BFI Working Paper Nov 16, 2020

Optimal Vaccine Subsidies for Endemic and Epidemic Diseases

Matthew Goodkin-Gold, Michael Kremer, Christopher M. Snyder, Heidi L. Williams
Topics:  COVID-19
BFI Working Paper Dec 7, 2020

Designing Advance Market Commitments for New Vaccines

Michael Kremer, Jonathan D. Levin, Christopher M. Snyder
Topics:  Health care, COVID-19